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Abstract  
 
INTRODUCTION 
Complementary Medicines (CMs) are widely available to the South African public. 
However, CMs have not yet been evaluated by the Medicines Control Council 
(MCC). The MCC has published new guidelines for the regulation of CMs, with 
which CM companies are required to comply.  
 
OBJECTIVE 
Determine to what degree Western Herbal CM labelling complies with the MCC’s 
requirements. 
 
METHODS 
Thirteen CM products containing recognised Western Herbal ingredients were 
selected from pharmacies in the northern suburbs of Johannesburg. Labelling 
information on the immediate and outer container labels, as well as the package 
inserts, was investigated. The relevant corresponding European Medicines Agency 
(EMA) monographs and MCC guidelines were used to assess compliance. 
 
RESULTS 
None of the products complied with the product dosage section of the monographs. 
Furthermore, the products contained indications that were not present in the 
monographs. The products did not fully meet the MCC’s mandatory minimum 
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labelling requirements, and they did not demonstrate total compliance with all of the 
MCC’s requirements for product labels and package inserts.  
 
CONCLUSION 
CM labelling is not fully compliant with the MCC’s requirements, and is required to 
undergo improvement in order to achieve MCC regulatory compliance. 
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Chapters 
 
1 Introduction 
 
 
The R8-billion Complementary Medicine (CM) industry (Kahn, 2015) is thriving in South 
Africa. CM is a broad term used to describe medicine practices that fall outside of the 
orthodox medicine system. The World Health Organisation (WHO) groups 
“Complementary/Alternative” Medicines, and describes these as practices that are not 
part of the country’s leading health care structure, and are also not part of the country’s 
traditional medicine (WHO, 2016). The WHO further describes that the terms 
“complementary” and “alternative” may be used interchangeably with traditional 
medicine in certain countries (WHO, 2016).   
The South African Minister of Health, together with the Medicines Control Council 
(MCC), defines CMs as medicines which originate from plants, animals or minerals, and 
are associated with the innate healing power of a human or animal (MCC, 2013c). 
Furthermore CMs are associated with the disciplines practiced by members of the Allied 
Health Professions Council of South Africa (AHPCSA) (MCC, 2013c). Examples of 
these disciplines include: Homoeopathy, Western Herbal Medicine and Traditional 
Chinese medicines (MCC, 2013a).  
In South Africa, traditional-use medicines are associated with African Traditional 
Medicine. The regulation of African Traditional medicines falls out of the scope of the 
CM regulations, as these apply only to disciplines associated with the AHPCSA (MCC, 
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2013a). Traditional medicine is associated with traditional philosophy, which 
encompasses indigenous African beliefs (Government Gazette, 2008).   
Despite the fact that CMs are widely used by the South African public (MCC, 2013a), 
CM regulation has not been fully implemented. The AHPCSA was established in 1982 
to regulate Allied Health Professionals (AHPCSA, 2015). However, the associated CMs 
for the AHPCSA disciplines have not yet been regulated.  
There is a false perception that CMs are safe, as they are “natural” (Health24, 2015). 
While orthodox medicines are not always of a “natural” origin they are required to 
demonstrate quality, safety and efficacy in order to be approved for use. Therefore, they 
must be produced in compliance with Good Manufacturing Practice (GMP) as stipulated 
by the South African Medicines Control Council (MCC) (MCC, 2010). Furthermore, 
safety and efficacy are required to be demonstrated through appropriate clinical studies 
(MCC, 2013a). CMs have not yet undergone the strict regulatory evaluation and 
approval that orthodox medicines undergo; therefore they may not contain the active 
ingredients that the labelling states they do, or they may contain potentially toxic 
ingredients. Any claims pertaining to quality, safety and efficacy have not been 
substantiated, and this poses a threat to public health.  
 
The MCC recognised that CMs are widely consumed yet unregulated, and they 
published Complementary and Alternative Medicines (CAMs) guidelines in 2013 (MCC, 
2013a). The guidelines specify what data is required to prove quality, safety and 
efficacy. Adhering to these guidelines poses a challenge to the CM industry, and in turn 
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to the MCC, which is the authority responsible for evaluating the data submissions. The 
CM industry faces having their products withdrawn from the market if they do not 
comply with the MCC’s regulations, and will need to invest a significant amount of 
resources to obtain MCC approval.  
This research project aims to provide information regarding the regulatory compliance of 
CMs currently available on the market. An important medicine regulation requirement 
pertains to appropriate product labelling. This is intended to provide consumers with 
information on how to use the product correctly to achieve efficacy, as well as provide 
important safety information such as warnings and contra-indications. The compliance 
of product labelling with regard to MCC requirements is investigated in this study.  
All CMs were mandated to comply with a specific set of minimum labelling requirements 
by 15 May 2014 (MCC, 2013b), and the achievement thereof will be determined in this 
research project. The study area is Western Herbal medicine, a CM discipline 
recognised by the MCC (MCC, 2013a). This is a significant discipline to study, as it has 
been approximated that almost 27% of the public consumes herbal medicines 
(Health24, 2015). Specifically, Western Herbals promoted for immune-enhancing effects 
will be studied. The MCC has created an appropriate category, “immune boosters”, for 
these CMs, and they are required to be submitted for registration by May 2016 (MCC, 
2013c).  
Immune boosters are often promoted for conditions such as the common cold. This is 
the most frequently occurring disease in humans (Van Schoor, 2014, p.14), and a likely 
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condition for which consumers will seek treatment. Therefore, immune boosters are a 
relevant category to study.  
Further relevance of the study of immune boosters is that immune boosters have the 
potential to be classified as high risk medicines. The Clinical Excellence Commission 
(CEC) of Australia (2016) defines high risk medicines as those that “have a high risk of 
causing injury or harm if they are misused or used in error” (CEC, 2016). Patients 
seeking treatment for a wide range of life-threatening diseases, such as HIV, TB or 
other infectious diseases that require effective orthodox therapies, may select and 
misuse an immune booster for their illness. The use of such inappropriate therapies will 
likely result in illnesses remaining untreated and progressing to a further deterioration in 
health, and possible death.  
 
2 Literature Review 
 
2.1 Complementary Medicine Regulation – a History in South Africa 
 
Historically, CMs were not required to undergo the strict regulatory approval process 
that orthodox medicines are subjected to. As a result, many products on the market are 
not MCC-approved as they have not been evaluated. In 2002 the MCC communicated, 
through a notice in the Government Gazette (No. 7282 R. 204), that CM companies 
were required to furnish the MCC with information regarding marketed products as well 
as those about to enter the market (MCC, 2013b). This enabled the MCC to conduct an 
audit regarding the status of CMs available to the public at the time (MCC, 2013b). This 
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was achieved through notifications submitted by CM companies (MCC, 2013b). 
Applicants were provided with a complementary registry number, which served to 
confirm that the notification had been received, but had not been evaluated or 
registered.  
While these notifications provided limited information, they were not registration 
applications and could not be assumed to be such (MCC, 2013b). Since the MCC was 
reliant upon companies providing them with the notification information, there was the 
potential for some companies not to comply. Therefore, the notification process needed 
to evolve into a set of clear guidelines. 
In July 2011 the Minister of Health proposed that the Regulations to the Medicines and 
Related Substances Act No. 101 of 1965 (hereafter referred to as Act 101 of 1965), 
were amended to include CMs (MCC, 2013b). CMs were allocated a specific medicine 
category, Category D, pertaining to CMs ready for use in humans and animals (MCC, 
2011). Amendments to labelling requirements were also proposed during this process 
(MCC, 2011).   
This proposal was updated and published in its final, legally-binding form in November 
2013 (MCC, 2013c). In December 2013, the MCC published guidelines relating to the 
regulatory requirements of CMs. These included one set of guidelines relating to the 
quality, safety and efficacy of CMs, and another comprising a roadmap for the 
implementation thereof (MCC, 2013a, 2013b). An important component of both sets of 
guidelines pertains to labelling requirements. 
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The MCC prescribes that if a current CM falls within one of the CM pharmacological 
categories it is required to be submitted for registration (MCC, 2013c), a mere 
amendment in the current medical claim is not permitted. No medicinal claims may be 
made, and the mandatory disclaimer is required to be present on the product label, 
package insert and patient information leaflet (MCC, 2013c).  
In September 2014, further amendments to Act 101 of 1965 were proposed and 
published for comment in Government Notice No. 37995 (MCC, 2014)  These proposed  
changes to the current definition of a CM, by expanding from where a CM could 
originate, and the indications for CMs such as the inclusion for diagnosis and treatment.   
 
2.1.1 Western Herbal Medicines 
 
For a product to be classified as a CM, it must fit the MCC’s definition thereof. Western 
Herbals meet this definition. They originate from plants, contribute to the human being’s 
innate healing ability, and fall under the scope of Phytotherapy.  
Phytotherapy is a discipline registered under the Allied Health Professions Act No. 63 of 
1982 (MCC, 2013a). The MCC recognises herbal substances that are referenced as 
such in formal literature, such as EMA community herbal monographs, Australian 
Therapeutic Goods Authority List of Substances, the German Commission C 
Monograph, the WHO monographs on Selected Medicinal Plants or British Herbal 
Pharmacopoeia, to name a few (MCC, 2013a). 
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2.1.2 Labelling Requirements  
 
CMs were required to comply with specific minimum labelling requirements by 15 May 
2014 (MCC, 2013b). Requirements included that the labelling appear in English and at 
least one other official language. Furthermore the label had to state the category of 
medicine, the pharmacological classification, the discipline of the medicine, and the 
statement: “This medicine has not been evaluated by the Medicines Control Council. 
This medicine is not intended to diagnose, treat, cure or prevent any disease.” (MCC, 
2013b). The complete labelling requirements for CMs are prescribed in Regulations 8, 9 
and 10 of Act 101 of 1965 (MCC, 2013b). Regulation 8 pertains to the product label, 
Regulation 9 to the package insert, and Regulation 10 to the patient information leaflet 
(MCC, 2013b).   
 
2.2 Regulation of Western Herbal Medicinal Products in the European 
Union 
 
The EMA requires that Western Herbals undergo regulatory approval. There are three 
options available when applying for marketing authorisation for these products (EMA, 
2014b). The application may be submitted as (1) a full application, (2) a well-established 
use, or (3) a traditional use (EMA, 2014b). A full application is required for a new herbal 
product, while a well-established application is used for herbal ingredients with ten 
years of proven medicinal use in the European Union (EU). Traditional use applies to 
products that have been in use for thirty years (EMA, 2014b). 
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For all three routes, the application must meet full quality requirements (EMA, 2014b). 
New applications require non-clinical data to demonstrate safety, and clinical trial data 
to demonstrate efficacy (EMA, 2014b). For both safety and efficacy, bibliographical data 
is acceptable for well-established use applications (EMA, 2014b). The safety and 
efficacy requirements for traditional-use applications are the least stringent. A 
bibliographical expert report may justify safety, while efficacy may be motivated using 
long-standing experience (EMA, 2014b). However, products that undergo the 
traditional-use approval pathway have restrictions on the product indications: that the 
product is non-prescription and may not be indicated for serious or chronic conditions 
such as cancer or diabetes (EMA, 2014b). Furthermore, traditional-use products may 
not be indicated for influenza (EMA, 2014b).  
 
 
2.3 European Medicines Agency Herbal Monographs 
 
The EMA monograph has undergone review and approval by the EMA’s Committee on 
Herbal Medicinal Products (EMA, 2015). The monograph contains information relating 
to the product’s safety and efficacy, and describes what the product should be used for 
(EMA, 2015). While there are other recognised monographs from which to select, for 
the limited scope of this research project the  EMA monograph will be used as the 
reference tool to assess the selected products’ labelling regarding quality, safety and 
efficacy.   
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2.4 The Industry’s Perspective 
 
The new legislative requirements have not been well received by various industry 
stakeholders in South Africa. It is estimated that 80% of CM products available on the 
market risk being withdrawn if they cannot meet the MCC’s requirements (Kahn, 2015). 
Therefore, CM companies are required to invest large sums of money in an effort to 
obtain the data required for product registration. Should the companies fail in this 
regard, they face the considerable financial loss of product withdrawal.   
The new regulations place an additional expectation on the CM industry, as well as on 
pharmacies, which are also seen to be in violation of the law if they sell non-compliant 
products (Kahn, 2015). Pharmacies and Pharmacists are governed by the South African 
Pharmacy Council (SAPC) and are required to obey the Pharmacy Act No. 53 of 1974 
as well as Good Pharmacy Practice, which is prescribed by the SAPC (SAPC, 2010). 
An important component of this is that pharmacists should not sell medicines for which 
they cannot confirm the quality, safety and efficacy (SAPC, 2010). Since CMs have not 
been MCC-approved, pharmacists selling CMs could be seen to be in violation of GPP. 
However, while pharmacies are governed by applicable laws, the law currently does not 
affect health shops, which in theory could continue to sell unapproved CM products. 
While the new requirements do place additional strain on the CM industry, the MCC has 
a responsibility to enforce these requirements. The MCC has been criticised for not 
having acted swiftly enough to control the availability of CMs. The MCC’s duty is to 
protect public health, and if available CMs have not been MCC-evaluated – at the very 
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least for quality – the public remains at risk of consuming unsafe and ineffective 
medicines (Jobson, 2009, p.511).  
 
 
3 Methodology  
 
A qualitative, descriptive study design was selected to collect and analyse the data, 
which was in the form of text presented on CM products available in South African 
pharmacies and health shops.  
 
 Study Setting 3.1
 
The demographic area chosen for this study was the northern suburbs of 
Johannesburg. This area was selected as it was likely to provide a large variety of the 
required CM products that cater to its affluent population. Statistics South Africa (2015) 
denotes Johannesburg as the largest city in South Africa and the capital of the country’s 
wealthiest province, Gauteng. As the country’s economic hub, Johannesburg has a 
large retail market with a broad scope of products to purchase. The city’s northern 
suburbs are in close proximity to the Sandton central business district. The City of 
Johannesburg (2015) describes the majority of this population as highly educated, well-
paid professionals. There is a wide selection of large-chain pharmacies in this area, as 
well as smaller, privately owned pharmacies and health shops. These pharmacies 
contain a wide selection of the various marketed brands of Western Herbal Medicines 
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and provided a broad sample of the immune-boosting Western Herbals required for this 
study.  
The study setting included major shopping malls and smaller suburban shopping 
centres in the suburbs of Killarney, Parkview, Hyde Park, Hurlingham, Bryanston and 
Benmore, so as to include as broad a scope of different outlets as possible. These are 
illustrated in the map below, which shows the proximity of these suburbs to the Sandton 
CBD (Figure 3-1).  
 
Figure 3-1 A map of the northern suburbs of Johannesburg which comprised the areas for sampling of 
products. 
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 Sampling 3.2
 
The unit of analysis was the individual CM product. The sampling was non-random and 
used purposive sampling. Products were selected using two inclusion criteria. The first 
was that product labelling contained claims indicating that the product could be used for 
immune-enhancing effects, as this is the study’s focus area. The second criterion was 
that the product contained one or more Western Herbal ingredients listed in the EMA 
monographs, as these are recognised as herbal medicines by the MCC (MCC, 2013a). 
Only one recognised body’s monograph was selected, based on the scope of this study. 
The EMA monographs were selected as the comparative monographs, as they provided 
comprehensive data and were readily available on the EMA website. Products 
specifically indicated for paediatric use were excluded from the sample, as the EMA 
monographs did not contain sufficient data on studies conducted in the paediatric 
population.  
 
 Data Collection 3.3
  
A qualitative data collection tool, in the form of a labelling assessment form, was 
created based on the product-specific EMA monograph, the MCC minimum 
requirements, and the labelling requirements of Act 101 of 1965. The template of this 
form can be found in Appendix 2.  
The data collection tool has three parts. The first contains a comparison of the product’s 
labelling with the information prescribed in the corresponding EMA herbal monograph. 
This was used to determine whether the product’s immediate and outer container 
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labels, as well as its package insert, contained accurate information pertaining to the 
quality, safety and efficacy sections of the monograph. The monograph was selected to 
be in the first part of the tool, as the information obtained from this section would be 
used to assess compliance in the two parts that followed. 
The EMEA monograph was used because it has undergone extensive review and 
approval by the EMA’s Committee on Herbal Medicinal Products (EMA, 2015), and 
therefore is a valuable reference tool with which to compare the information presented 
on the studied products. The monographs were easily located on the EMA website, and 
provided comprehensive data with which to compare the study products. Table 3-1 
indicates which of the headings contained in the EMA monograph correspond to quality, 
safety or efficacy information. Posology is a term used by the EMA to describe the 
dosage and dosage frequency.  
 
Table 3-1 Headings of the European Medicines Agency monograph that correspond to quality, safety and 
efficacy of medicines on the product label and package insert. 
Monograph heading Corresponding aspect of 
quality, safety and efficacy 
 
Where this is found on 
medication 
Qualitative and quantitative 
composition 
 
Quality Immediate label, outer label, 
package insert 
Pharmaceutical form Immediate label, outer label, 
package insert 
 
Therapeutic indications Efficacy Immediate label, outer label, 
package insert 
 
Posology Immediate label, outer label, 
package insert 
 
Duration of use Immediate label, outer label, 
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package insert 
 
Method of administration Immediate label, outer label, 
package insert 
Contra-indications 
 
Safety Package insert 
Special warnings and precautions 
for use 
 
Immediate label, outer label, 
package insert 
Interactions with other medicinal 
products and other forms of 
interaction 
 
Package insert 
Pregnancy and lactation Immediate label, outer label, 
package insert 
Effects on ability to drive and use 
machines 
 
Package insert 
Undesirable effects 
 
Package insert 
Overdose Package insert 
 
The second part of the data collection tool was used to assess whether the product 
labelling satisfied the MCC’s minimum prescribed information requirements, which 
should have been implemented by 15 May 2014 (MCC, 2013). This was chosen to be 
the second part, since the information required is mandatory and provides a direct 
conclusion regarding compliance or lack thereof.  
The third part of the data collection tool was used to assess whether the product 
labelling complied with the requirements of Regulations 8, 9 and 10 of Act 101 of 1965. 
These are the requirements for the labels on the immediate and the outer container 
(carton), the package insert, and the patient information leaflet. The requirements for 
the immediate container label and outer container label are presented in Table 3-2. The 
requirements for the package insert and patient information leaflet are presented in 
Table 3-3. 
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Table 3-2 Information required for immediate container label and outer container label of medicine according 
to Regulation 8 of Act 101 of 1965. 
Requirement Immediate 
container 
label 
Outer 
container 
label 
Clearly legible indelible letters in English  
 
Required Required 
Clearly legible indelible letters in at least one other official language 
 
Required Required 
Scheduling status (where applicable) Required Required 
Proprietary name of the medicine Required Required 
Registration / reference number Required Required 
Dosage form  Required Required 
Approved name of each active ingredient of the medicine  Required Required 
Quantity thereof contained in a dosage unit, or per suitable mass or volume or 
unit 
 
Required Required 
Name and percentage of any bacteriostatic or bactericidal agent which has been 
added to the medicine as a preservative 
 
Required Required 
Approved name of any anti-oxidant contained in the medicine Required Required 
Quantity of sugar contained in the medicine 
  
Required Required 
Quantity of ethyl alcohol contained in the medicine, expressed as a percentage of 
the total volume of the medicine if such quantity exceeds two per cent by 
volume 
 
Required Required 
Content of the medicine package expressed in the appropriate unit or volume of 
the medicine 
 
Required Required 
Approved indications for use of the medicine Required Required 
Recommended dosage of the medicine Required Required 
Where applicable, the instruction 'Shake the bottle before use' Required Required 
Lot number Required Required 
Expiry date Required Required 
Name of the holder of certificate of registration (or name of applicant) Required Required 
Storage temperature and other precautions required for the preservation of the 
medicine 
 
Required Required 
The warning: 'Keep out of reach of children' Required Required 
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Table 3-3 Requirements for the package insert and patient information leaflet according to regulation 9 and 
10 of Act 101 of 1965. 
Package insert 
 
Patient information leaflet 
Clearly legible text in English   
 
Information in English   
 
Clearly legible text in at least one other official 
language 
 
Information in at least one other official language 
 
Scheduling status (where applicable) 
 
Scheduling status  
 
Proprietary name and dosage form 
 
Proprietary name and dosage form 
 
The approved name of each active ingredient  
 
Quantity thereof contained in a dosage unit or 
per suitable mass or volume or unit of the 
medicine 
 
Composition of the medicine  
(information contemplated in Regulation 9) 
The approved name and quantity of any 
bactericidal or bacteriostatic agent included in 
the medicine as a preservative, expressed as a 
percentage 
 
The quantity of ethyl alcohol included in a 
preparation for oral or parenteral administration, 
if such quantity exceeds two per cent by volume 
 
The words "contains TARTRAZINE" should the 
medicine contain such ingredient 
 
"contains sugar" or "sugar free" whichever is 
applicable 
 
Pharmacological classification 
 
 
 
Pharmacological action 
 
 
Indications 
 
The approved indications and use 
 
Instructions on how to take the medicine, 
including the following statement:   
"Do not share medicines prescribed for you with 
any other person." 
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Package insert 
 
Patient information leaflet 
Contra-indications 
 
Contra-indications 
Warnings 
  
Warnings 
Interactions 
 
Interactions 
 
The statement:  
"If you are taking medicines on a regular basis, 
using the medicine at the same time with 
another medicine may cause undesirable 
interactions. Please consult your doctor, 
pharmacist or other health care professional for 
advice."  
 
Pregnancy and lactation 
 
The statement:  
“If you are pregnant or breast-feeding your baby 
while taking this medicine please consult your 
doctor, pharmacist or other health care 
professional for advice.” 
 
Dosage and directions for use 
 
Instructions on how to take the medicine, 
including the following statements:   
"Do not share medicines prescribed for you with 
any other person."  
 
"In the event of over dosage, consult your doctor 
or pharmacist. If neither is available, contact the 
nearest hospital or poison control centre” 
 
Side effects and special precautions 
 
Precautions 
  
Side effects, including the following general 
statement:   
"Not all side effects reported for this medicine 
are included in this leaflet. Should your general 
health worsen while taking this medicine, please 
consult your doctor, pharmacist or other health 
care professional for advice" 
 
Known symptoms of over dosage and particulars 
of its treatments 
 
The statement: 
"In the event of over dosage, consult your doctor 
or pharmacist. If neither is available, contact the 
nearest hospital or poison control centre" 
 
Identification Identification of the medicine, i.e. the description 
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Package insert 
 
Patient information leaflet 
 of its physical appearance as tablet, capsule, etc.   
 
Presentation 
 
Presentation, which includes the number, volume 
or mass per package unit and a description of the 
packaging material, e.g. bottle, blister pack, etc. 
 
Storage instructions, including storage 
temperatures 
 
Storage and disposal information, including the 
following general statement:   
"Store all medicines out of reach of children." 
 
Reference number (where applicable) followed 
by the expression "Act 101/1965" 
 
Registration number of the medicine 
Name and business address of the holder of the 
certificate of registration / applicant 
 
Name, business address and telephone number 
of the holder of the certificate of registration 
Date of publication of the package insert (where 
applicable) 
 
The date of publication of the patient information 
leaflet 
 
 
 Data Analysis 3.4
 
Each product was recorded on a separate data collection checklist using the product’s 
allocated designation, e.g. Product A. The corresponding product labelling information 
was captured on the relevant checklist under the “product label” column. An evaluation 
of the three sections of the data collection tool was conducted and the corresponding 
findings were recorded on the checklist, either in the “complies” or the “non-compliant” 
column. Compliant status was given if the product clearly contained the applicable 
information. Non-compliant status was allocated if the product contained information 
that did not correspond with that indicated in the monograph, or if the required 
information was not stated at all. 
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In cases where the product could not clearly be given a compliant or non-compliant 
status, a “partially compliant” status was given, together with an explanation. The 
findings were captured on an Excel® spreadsheet in tabular format. This allowed for 
analysis of the individual product with each aspect of the requirements, as well as 
comparison among the various products. The data was classified and colour-coded for 
its degree of compliance. 
The product’s immediate and outer container labels, together with its package insert, 
were assessed in comparison with the monograph. Compliance with the monograph 
was determined using the Clinical Particulars headings prescribed under the 
monograph template. The Pharmacological Properties section was not included as 
there was either very little or no information present under this section in the 
monograph. Each product was assessed for compliance with each heading of the 
corresponding monograph. Compliance was confirmed if the information in the 
corresponding sections of the product’s labels or package insert agreed with the 
monograph. Compliance with posology was determined by calculating the dosages a 
patient would receive if they followed the dosage instructions provided on the product 
labelling, and comparing this with the information contained under posology. 
Compliance with the MCC’s minimum prescribed information was determined by 
assessing the product’s immediate and outer container labels for the presence of the 
required language text. Each labelling component had to include both English and 
another official language in order for the products to be deemed compliant. Products 
were deemed partially compliant if only some of the text was in both languages. 
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To be deemed compliant, information had to be provided under the Category, 
Classification and Discipline sections. If this information was absent, non-compliant 
status was allocated. The absence or presence of the MCC-prescribed statement, “This 
medicine has not been evaluated by the Medicines Control Council. This medicine is not 
intended to diagnose, treat, cure or prevent any disease” was noted. The absence of 
this statement deemed the product non-compliant.  
The product’s immediate and outer labels were inspected to detect the presence of any 
medicinal claims. If the product alluded to having a direct healing effect, or assured 
safety, this would qualify as a claim. 
A product’s immediate and outer labelling, and its package insert (where present), were 
assessed for compliance with Regulations 8 and 9 of Act 101 of 1965, by using the data 
collection tool to compare the product labelling with the information required by the 
regulations. Where no information was provided for any of the headings, non-compliant 
status was allocated. In order to determine compliance with Regulation 10 of Act 101 of 
1965, products were examined for the presence of a patient information leaflet. Since a 
detailed analysis was provided in the EMA monograph section, the safety and efficacy 
information required by the MCC was only assessed to the point of confirming that 
information was provided under headings such as indications, contra-indications, 
dosage and warnings. 
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4 Results and discussion 
 
 Products 4.1
 
Nine stores were visited. Products were purchased on visits to four privately owned 
pharmacies (one of which had a health shop inside it), one health shop, two Pharmacy 
Chain A stores and two Pharmacy Chain B stores. Due to the diminishing presence of 
private pharmacies, there were fewer of these than there were chain pharmacies. Two 
of each chain store were selected in order to determine if there were different products 
available in the larger stores. The health shop visited only sold food supplements and 
therefore no product was purchased there.  
Each store had a different approach to displaying the products selected for the study. In 
some stores, products from various companies were kept under the immune-enhancing 
product section. An example of this is Chain store A, which classified the products 
under “Immune Focus”. Other stores merchandised products by manufacturer, and 
displayed various categories of products together. Some of the products for this study 
were found at the checkout counter, as part of a promotion. Products were selected if 
they had not been present at another store, so as to gather as broad a product range as 
possible. A wide range of oral dosage forms was selected. These included tinctures, 
tablets, capsules, effervescent tablets and throat sprays. In order to obtain a broad 
reflection of the current status of CM product labelling, thirteen products from various 
stakeholders were purchased, as presented in Table 4-1.  
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Table 4-1 Summary of the products selected for the study. 
Product Active 
ingredient(s) 
 
Dosage 
form  
Monograph used Information 
sources 
Product A 
 
Echinacea 
purpurea herba  
 
Echinacea 
purpurea root 
Liquid drops Echinacea purpurea (L.) 
Moench, herba recens  
 
Echinacea purpurea (L.) 
Moench, radix 
 
Immediate label 
Outer container 
label 
Package insert 
Product B 
 
 
Echinacea 
purpurea herba  
 
Echinacea 
purpurea root  
Tablets Echinacea purpurea (L.) 
Moench, herba recens  
 
Echinacea purpurea (L.) 
Moench, radix 
 
Immediate label 
Outer container 
label 
Package insert 
Product C 
 
 
Echinacea 
purpurea  
Effervescent 
tablets 
Echinacea purpurea (L.) 
Moench, radix 
 
Echinacea purpurea (L.) 
Moench, herba recens 
 
Immediate label 
Outer container 
label 
Package insert 
Product D 
 
Black elderberry 
extract 
(Sambucus 
nigra)  
 
Tablets Sambucus nigra L., Flos Immediate label 
Package insert 
Product E 
 
Pelargonium 
sidoides root  
Liquid: 
throat spray 
Pelargonium sidoides DC  Immediate label 
Outer container 
label 
Package insert 
 
Product F 
 
Pelargonium 
sidoides  
 
Effervescent 
tablets 
Pelargonium sidoides DC Immediate label 
Outer container 
label 
Package insert 
 
Product G 
 
 
 
Pelargonium 
sidoides root 
 
Sambucus nigra  
 
Tablets Pelargonium sidoides DC 
 
 
Sambucus nigra L., Flos 
Immediate label 
Outer container 
label 
Package insert 
Patient 
Information 
Leaflet 
 
Product H 
 
Sambucus nigra  Capsules  Sambucus nigra L., Flos Immediate label 
Outer container 
label 
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Product Active 
ingredient(s) 
 
Dosage 
form  
Monograph used Information 
sources 
Product I 
 
Sambucus nigra  
Pelargonium 
sidoides  
 
Liquid: 
throat spray 
Pelargonium sidoides DC 
 
Sambucus nigra L., Flos 
Immediate label 
Outer container 
label 
Package insert 
 
Product J 
 
Echinacea 
extract                   
 
Elderberry 
extract 
(Sambucus 
nigra)  
 
 
Tablets Echinacea angustifolia 
DC., radix 
 
Echinacea purpurea (L.) 
Moench, radix 
 
Echinacea purpurea (L.) 
Moench, herba recens 
 
Sambucus nigra L., Flos 
 
Immediate label 
Outer container 
label 
Package insert 
Product K 
 
Echinacea 
extract  
 
Elderberry 
(Sambucus 
nigra)  
 
 
 
Capsules Echinacea angustifolia 
DC., radix 
 
Echinacea purpurea (L.) 
Moench, radix 
 
Echinacea purpurea (L.) 
Moench, herba recens 
 
Sambucus nigra L., Flos 
 
Immediate label 
 
Product L 
 
 
Echinacea 
purpurea  
 
Effervescent 
tablets 
Echinacea purpurea (L.) 
Moench, radix 
 
Echinacea purpurea (L.) 
Moench, herba recens 
 
Immediate label 
Outer container 
label 
Package insert 
Product M 
 
Echinacea  
 
Capsules Echinacea angustifolia 
DC., radix 
 
Echinacea purpurea (L.) 
Moench, radix 
 
Echinacea purpurea (L.) 
Moench, herba recens 
Immediate label 
Outer container 
label 
Package insert 
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Where product labelling was non-specific as to which herbal plant part or species was 
present in the formulation (such as Echinacea, which may be a Purpurea or 
Angustifolia), all available monographs were used for comparison. This was done to 
broaden the study, by checking that if one area appeared non-compliant, it could be 
compliant with another monograph. The labelling on some of the products containing 
Echinacea did not indicate whether the Echinacea radix (root) or herba recens (fresh 
herbal extract) was used.  
The Echinacea purpurea monograph for the herba recens contains both the well-
established use and the traditional use. The well-established use was selected as it 
contains the indication for the common cold, while the traditional use was cutaneous, for 
treating dermal wounds. Some of the products also contained vitamins and minerals, or 
other herbal ingredients which were potentially related to another CM discipline. Only 
the herbal ingredients that had a corresponding monograph were included in the study. 
  
 European Medicines Agency Herbal Monographs  4.2
 
The monographs were located on the EMA website. One was located for Sambucus 
nigra and another for Pelargonium sidoides. Three monographs were found for 
Echinacea, namely Echinacea purpurea radix, Echinacea purpurea herba recens and 
Echinacea angustifolia. 
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4.2.1 Qualitative and Quantitative Composition 
 
The monographs are specific as to what the composition for each herbal ingredient 
should be. The composition is required to be either a herbal substance or a herbal 
preparation. The herbal preparation category is further divided into herbal substances, 
tinctures, and dry or liquid extracts. The labelling of the various products was assessed 
and as far as possible compliance with the required composition was determined. None 
of the products were deemed fully compliant with the qualitative and quantitative 
composition stipulated by the corresponding monograph.  
Product E provided conflicting information on the immediate container label (136,25 
mg/ml), outer container label (138 mg/ml), and the package insert (234 mg) regarding 
the active ingredient composition quantity. The quantity value of 138mg/ml was chosen 
for the posology assessment in Table 4-5.  
Further insight into the quality and manufacturing processes is required to verify the 
herbal ingredient composition. However, the results from this section of the study 
highlight that quality aspects (such as information about the active herbal ingredients) 
are not verified, and therefore the safety and efficacy of the CM is not substantiated.  
  
4.2.2 Pharmaceutical Form 
 
Most of the products (85 %) appeared to comply with the corresponding monograph’s 
pharmaceutical forms. This percentage of compliance was determined by  excluding  
the Sambucus nigra component in the combination products, as this should be in liquid 
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form, and excluding two of the products for which compliance could not be determined.  
The solid dosage form products containing Sambucus nigra did not comply as this is 
supposed to be in the form of either a herbal tea or an oral liquid. An exception to this 
was Product H, whose compliance could not be fully determined as it was stated to be 
equivalent to fresh juice.  
Kinoshita et al. (2012, p.1637) noted that their study on Sambucus nigra demonstrated 
a stronger in vivo than in vitro effect against the Human Influenza A virus. This was 
dissimilar to results from other studies. The authors propose that this may be because 
they used the concentrated juice of elderberry, while other researchers may have used 
commercial preparations for which the exact extraction methods were not known 
(Kinoshita et al, 2012, p.1637) therefore, the pharmaceutical form has a direct influence 
on efficacy. 
The effect of pharmaceutical form is further emphasised in a study by Roxas and 
Jurenka (2007, p. 40), where it was proposed that the varied conclusions into 
Echinacea’s efficacy may result from the part of the plant studied, as well as the 
extraction process used. It is therefore imperative that manufacturers and regulators 
ensure the correct form is used.  
 
4.2.3 Therapeutic Indications 
 
All the products contained more indications than the monographs, and were therefore 
only partially compliant. The majority of the products were indicated for the treatment of 
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colds and flu, while their corresponding monographs indicated the treatment of colds 
only.   
4.2.3.1 Products Containing Echinacea 
 
According to the therapeutic indications of the monograph, Echinacea purpurea radix 
(EMA, 2010) and Echinacea angustifolia radix (EMA, 2012a) are indicated for 
supportive treatment of the common cold. Echinacea purpurea herba recens (EMA, 
2014a) is indicated for the short-term prevention and treatment of the common cold. 
Table 4-2 summarises the therapeutic indications on the medication label, compared 
with the indications listed in the monograph. 
 
Table 4-2 Therapeutic indications on the label for products containing Echinacea, compared with European 
Medicines Agency monograph (compliant indications in normal text and non-compliant indications in bold). 
Product  Indications on medication label and/or package insert (PI) 
 
Product A  
 
Immediate container label: “A herbal remedy recommended for the prevention and 
treatment of: colds, influenza type infections and similar upper respiratory tract 
conditions, sore throat, recurring winter ills and lower urinary tract infections. 
Assists to modulate the immune response to infections.” 
 
Outer container label and package insert: “A herbal remedy with supportive therapy 
for the prevention and treatment of colds, influenza type infections and similar upper 
respiratory tract conditions, sore throats and mild lower urinary tract infections. 
Assists to modulate the immune response to infections.” 
 
Product B 
Product C Label “Immune booster” 
“Echinacea’s action is primarily directed toward the immune system. This herb has 
demonstrated antibacterial, anti-inflammatory, antiseptic and immune system 
enhancing properties.” 
 
Product J Claim specific to Echinacea: 
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“Assists to maintain and support the immune system.” 
 
Product K 
 
“Assists in the prevention and relief of Cold and Flu symptoms.” 
Product L PI Echinacea purpurea ext.: 
“Herbal extract with a stimulant effect on the immune system, increasing the body’s 
natural resistance to infections, especially colds and flu.” 
 
Product M PI Echinacea:  
 
“Aids in the treatment and prevention of colds and flu and related infections. 
Exerts an immune stimulatory and anti-inflammatory effect to reduce the severity 
and duration of the symptoms commonly associated with colds and flu.” 
 
 
These products were assessed to be non-compliant because of indications not stated in 
the monograph, such as the indication for the prevention of colds and flu. However, 
Jawad et al. (2012, p.2) conducted a clinical trial in human subjects using Echinaforce® 
Drops (a product containing Echinacea) as a four-month therapy to determine if it had a 
prophylactic effect against the common cold. The study group who received these drops 
had a smaller incidence of experiencing a common cold episode. This may support the 
indication for cold prevention, and it was concluded that the long-term use (four months) 
of Echinaforce® Drops could be supported (Jawad et al., 2012, p.6).   
In a pre-clinical study by Hudson and Vimalanathan (2011, p.1025) it was determined 
that Echinaforce® Drops showed activity against viruses with membranes. These 
viruses included Influenza A and B (Hudson and Vimalanathan, 2011, p.1025). These 
findings may support indications for influenza-type infections. Another pre-clinical study 
by Fusco et al. (2010, p.2) used mice infected with influenza and investigated the 
effects of Echinacea purpurea herbal extract. The study showed that influenza-infected 
mice administered with the Echinacea showed better clinical outcomes than those 
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which were not (Fusco et al., 2010, p.4). The indications for influenza may therefore be 
supported. However, further clinical research is required.  
4.2.3.2 Products Containing Sambucus  
 
The monograph for Sambucus nigra indicates its use in the relief of early symptoms of 
the common cold (EMA, 2008). Table 4-3 summarises the therapeutic indications on the 
medication labels of products containing Sambucus, as compared to the monograph. 
 
Table 4-3 Therapeutic indications on the label for products containing Sambucus, as compared to the 
European Medicines Agency monograph (compliant indications in normal text and non-compliant indications 
in bold).  
Product  Indications on medication label and/or package insert (PI) 
 
Product D “Contributes to a healthy immune system.” 
PI: “Assists in supporting the function of the immune system and may help to 
soothe the minor symptoms associated with colds and flu.” 
 
Product G “For the symptomatic relief of colds and flu.” 
 
Product H “Cold and Flu 
Congestion 
Cough 
Aches & Pains 
Fever 
Sore throat” 
 
Product I “Soothes and protects against cold and flu symptoms” 
 
Product J “Assists to reduce cold and flu symptoms due to its anti-congestion properties” 
 
Product K “Assists in the prevention and relief of Cold and Flu symptoms.” 
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The products containing Sambucus nigra complied with the monograph indications 
pertaining to colds. However, these products were deemed non-compliant with respect 
to the additional indications related to flu. Roxas and Jurenka (2007, p.40) describe that 
two randomised, double-blind, placebo-controlled studies using the product Sambucol™ 
(which contains Sambucus) supported the indication for flu. In these studies Sambucol™ 
showed activity against Influenza A and B. Zakay-Rones et al. (2004, p.137) explain 
that Sambucus could be effective in the treatment of flu, as it has been shown that 
Sambucus can inhibit the adhesion of the influenza virus to body cell receptors.  
4.2.3.3 Products Containing Pelargonium 
 
The monograph for Pelargonium sidoides indicates its use in the symptomatic treatment 
of the common cold (EMA, 2012b). Table 4-4 summarises the therapeutic indications on 
the labels of products containing Pelargonium, as compared to the monograph.  
Table 4-4 Therapeutic indications on the label for products containing Pelargonium, as compared to the 
European Medicines Agency monograph (compliant indications in normal text and non-compliant indications 
in bold). 
Product  Indications on medication label and/or package insert (PI) 
 
Product E “Infection support associated with colds and flu.” 
 
“Pelargonium sidoides can assist the body with immune support and to relieve 
symptoms associated with the common cold as well as acute and chronic 
respiratory infections.” 
 
“Can assist the body with: 
Anti-viral support 
Anti-bacterial support 
Infection support associated with colds and flu 
Immune support 
Symptomatic relief” 
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Product F Label: “Infection support associated with colds and flu. Hay fever support” 
PI: “Pelargonium sidoides can assist the body with symptomatic relief associated 
with respiratory tract infections. The active ingredients can also provide hay fever 
support.” 
Product G “For the symptomatic relief of colds and flu.”  
 
Product I “Soothes and protects against cold and flu symptoms.” 
 
 
The products containing Pelargonium all followed the same trend in that they were 
compliant in their indications for the common cold, but were non-compliant in their 
indications for flu.  
4.2.4 Posology 
 
Every product was found to be non-compliant when compared with the posology 
required by its corresponding monograph (Table 4-5). A trend identified across six of the 
products was that they contained the dosage and directions for use for children, where 
the corresponding monograph did not recommend the use in children under 12 years 
old.  
Table 4-5 Summary of comparison between dosage and maximum daily dosage between the medication label 
and/or package insert, and the European Medicines Agency monograph. 
 
  Medication label and/or package 
insert 
 
EMA 
monograph 
 
Product  Active 
ingredient 
Strength/quantity 
per dosage form 
Maximum 
recommended 
daily dosage 
 
Recommended 
daily dosage 
Conclusion 
 
Product 
A 
Echinacea 
purpurea 
614 mg/ml 
 
 E. purpurea 
herba recens* 
N/A 
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  Medication label and/or package 
insert 
 
EMA 
monograph 
 
Product  Active 
ingredient 
Strength/quantity 
per dosage form 
Maximum 
recommended 
daily dosage 
 
Recommended 
daily dosage 
Conclusion 
 
Herba 
 
Echinacea 
purpurea 
Root / radix 
 
32 mg/ml 160 mg 360 mg Underdose 
Product 
B 
Echinacea 
purpurea 
Herba 
 
1 140 mg per tablet  E. purpurea 
herba recens* 
N/A 
Echinacea 
purpurea 
Radix 
 
60 mg per tablet 
 
180 mg 360 mg 
 
Underdose 
Product 
C 
Echinacea 
purpurea 
50 mg per tablet 
 
50 mg  E. purpurea 
radix: 360 mg 
 
E. purpurea 
herba recens* 
 
Underdose 
 
 
N/A 
Product 
D 
Black 
elderberry 
extract 
(Sambucus 
nigra) 
 
50 mg per tablet 200 mg Sambucus nigra 
15 000 mgɫ  
 
Underdose 
Product 
E 
Pelargonium 
sidoides root 
 
138 mg/ml** 6 624 mg Pelargonium 
sidoides 60 mg 
Overdose  
Product 
F 
 
Pelargonium 
sidoides  
 
350 mg per tablet 1 050 mg 60 mg Overdose 
Product 
G 
Pelargonium 
sidoides root 
 
20 mg per tablet 20 mg 
 
Pelargonium 
sidoides 60 mg 
Underdose 
 
Sambucus 
nigra 
 
20 mg per tablet 20 mg Sambucus nigra 
15 000 mgɫ  
 
Underdose 
Product 
H 
Sambucus 
nigra  
3 800 mg per 
capsule 
 
22 000 mg Sambucus nigra 
15 000 mgɫ 
Overdose 
Product I Elderberry 
extract 
250 mg/ml 9 g 
 
Sambucus nigra 
15 000 mgɫ  
Within the 
range of  
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  Medication label and/or package 
insert 
 
EMA 
monograph 
 
Product  Active 
ingredient 
Strength/quantity 
per dosage form 
Maximum 
recommended 
daily dosage 
 
Recommended 
daily dosage 
Conclusion 
 
(Sambucus 
nigra) 
 
 
6-15 g per 
day  
 
Pelargonium 
extract 
(Pelargonium 
sidoides 
12,5%) 
 
136 mg/ml 4 896 mg Pelargonium 
sidoides 60 mg 
Overdose 
Product 
J 
Echinacea 
extract  
80 mg per tablet 240 mg E. angustifolia 
1 500 mg  
 
E. purpurea radix 
360 mg 
 
E. purpurea 
herba recens* 
 
Underdose 
 
 
 
Underdose  
 
 
N/A 
Elderberry 
extract 
(Sambucus 
nigra) 
 
20 mg per tablet 60 mg Sambucus nigra 
15 000 mgɫ 
Underdose 
 
 
Product 
K 
 
Echinacea 
extract 
 
 
100 mg per capsule 
 
 
800 mg 
 
 
E. angustifolia 
1 500 mg  
 
E. purpurea radix 
360 mg 
 
E. purpurea 
herba recens *  
 
 
 
Underdose 
 
 
Overdose 
 
 
 
N/A 
Elderberry 
(Sambucus 
nigra) 
 
100 mg per capsule 800 mg Sambucus nigra 
15 000mgɫ 
 
Underdose 
Product 
L 
Echinacea 
purpurea 
240 mg per tablet 240 mg E. purpurea radix 
360 mg 
 
E. purpurea 
herba recens* 
Underdose 
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  Medication label and/or package 
insert 
 
EMA 
monograph 
 
Product  Active 
ingredient 
Strength/quantity 
per dosage form 
Maximum 
recommended 
daily dosage 
 
Recommended 
daily dosage 
Conclusion 
 
 
Product 
M 
Echinacea 75 mg per capsule 225 mg 
 
E. angustifolia 
1 500 mg  
 
E. purpurea radix 
360 mg 
 
E. purpurea 
herba recens* 
 
Underdose 
 
 
Underdose 
 
 
 
N/A 
 
Key:  
 
* Echinacea purpurea herba recens: Dose compliance could not be determined, as the 
monograph provides the posology in terms of expressed juice. 
 
** Strength as provided on the outer container label (conflicting data was present on the 
labelling components). 
 
ɫ Sambucus nigra: Based on the posology for the herbal substance for tea preparation.  
 
 
 
 
 
4.2.5 Duration of Use 
 
The monographs for each herbal substance stipulate for how long the product should be 
used, and whether medical attention is required after a stipulated amount of time. All the 
products were non-compliant in that the duration of use was not stated. This poses a 
risk that patients may continue to use products without symptom improvement and 
neglect to seek medical assistance.  
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4.2.6 Contra-indications, Special Warnings and Precautions for Use 
 
All the products, with the exception of two, complied with the corresponding monograph 
contra-indications. Two products were deemed non-compliant as they did not provide 
any contra-indications. Only one product fully complied with the special warnings and 
precautions for use. Products were seen to partially comply if their labelling contained 
some of the information contained under the heading.  
The warnings and special precautions in the Pelargonium sidoides monograph included 
those related to hepatotoxicity (EMA, 2012b). Two of the products were non-compliant, 
as none of their warnings correlated to those in the EMA monograph. However, both 
contained warnings related to the blood-thinning effect of Pelargonium and carried a 
warning regarding interactions with warfarin or other such medications. Patrick and 
Hickner (2008, p.160) describe that Pelargonium contains plant coumarins, and that in 
theory there are possible medicine interactions with anti-coagulants. However, the 
authors state that there have not been any serious adverse events related to bleeding 
(Patrick and Hickner, 2008, p.160). In a study by Brendler and van Wyk (2008, p.429), 
the authors affirmed that the coumarins identified in the study’s extract of Pelargonium 
did not appear to exert anti-coagulant effects.  
 
4.2.7 Pregnancy and Lactation 
 
All the monographs, except one, contained a statement that the use of the herbal 
product was not recommended during pregnancy, as there was not enough relevant 
safety data. The exception was the monograph for Echinacea purpurea herba recens, 
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which stated that while some data was available, a doctor should be consulted before 
use during pregnancy (EMA, 2014a).  
Only two products complied with their corresponding monographs. The remainder of the 
products were non-compliant for various reasons. Non-compliance was determined for 
products containing labelling which stated that no side effects had been recorded, 
instead of stating that there was a lack of data. This could mislead a patient into thinking 
that the product is safe. Non-compliance was allocated for products containing 
statements that allowed for consultation with a healthcare practitioner, as this carries 
the risk that an insufficiently informed person may be consulted. Non-compliance was 
allocated for products which only stated that use in pregnancy and lactation has not 
been established, rather than stating that it is not recommended.  
 
4.2.8 Effects on Ability to Drive and Use Machines 
 
All five product monographs stated that no studies had been conducted in this area. 
Although one product provided information in this category, it did not comply. It stated 
that it was safe to drive during product use. This was untrue as the specific monograph 
stated that there was no data available.  
 
4.2.9 Undesirable Effects 
 
The undesirable effects for the three monographs for Echinacea ranged from dermal to 
severe hypersensitivity reactions. Products A, B, C and L partially complied in that they 
listed hypersensitivity reactions but did not specify all the reactions listed in the 
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monographs. Product M was non-compliant as it only listed gastrointestinal 
disturbances, which did not appear in the monographs.  
The monograph for Sambucus nigra describes that there are no known undesirable 
effects, but that if any adverse reactions occur, medical consultation is to be sought 
(EMA, 2008). Product D partially complied as it stated there were no known side effects, 
but it did not advise seeking medical advice.  
Some of the undesirable effects listed in the Pelargonium sidoides monograph included 
gastrointestinal effects, nasal bleeding, allergic reactions and hepatotoxicity (EMA, 
2012b). Product E partially complied in that it carried the advice that medical attention 
should be sought if any side effects were experienced. Product F carried the same 
advice, but was non-compliant as it further stated that there were no reported side 
effects. However, both products contained symptoms in the overdosage section that 
were similar to those listed in the monograph’s undesirable effects.  
Products G and I stated that there were no known side effects, which made them non-
compliant with the Pelargonium requirements, and compliant with the Sambucus 
requirements. Similarly, Product J did not comply as it stated that there were no known 
side effects, which is not true for the Echinacea ingredients. Products H and K were 
non-compliant as they did not state any side effects.    
   
4.2.10 Overdose 
 
All the monographs stated that there were no reported overdose cases. The products 
were compliant if relevant safety information was provided under this section, such as 
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advice to seek medical assistance in the event of an overdose. Six of the products did 
not contain any information and were deemed non-compliant. 
  
 Compliance with MCC Requirements 4.3
 
This was determined by investigating whether the product fully complied with the 
requirements or did not comply at all. Partial compliance with the requirement to provide 
text in one other official language was allocated for products that contained only part of 
the text in another language. Partial compliance was also allocated in instances where 
the required phrase pertaining to medical assistance was provided, but was not identical 
to the MCC’s wording. 
 
Table 4-6 Summary of number of products (n=13) complying with Medicines Control Council (MCC) minimum 
criteria and actual medication label. 
MCC minimum criteria  Number of 
products 
complying 
Number of 
products 
partially 
complying 
 
Number of 
products non-
compliant 
Written in English and at least one 
other official language  
 
2 1 10 
Category of medicine 
 
1 0 12 
Pharmacological classification of the 
medicine  
 
1 0 12 
Discipline of medicine  
 
1 0 12 
The words: “This medicine has not 
been evaluated by the Medicines 
Control Council. This medicine is not 
6 0 7 
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MCC minimum criteria  Number of 
products 
complying 
Number of 
products 
partially 
complying 
 
Number of 
products non-
compliant 
intended to diagnose, treat, cure or 
prevent any disease.” 
 
All claims relating to symptoms must 
be accompanied by the advice: “If 
symptoms persist consult your 
healthcare practitioner.” 
 
4 3 6 
No medicinal claims: 
Immediate label 
 
11 0 2 
Carton 
 
13 0 0 
Package insert 
 
13 0 0 
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Figure 4-1 Graph illustrating number of products (n=13) complying with Medicines Control Council (MCC) 
minimum criteria and actual medication label. 
 
The category of medicine and the pharmacological classification were provided on the 
immediate and outer labels of product G only. For the other products this information 
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was provided only in the package insert. Product G was also the only product to provide 
the discipline of the medicine on its label.  
Eleven of the products did not contain direct medicinal claims, as phrases such as 
“soothes”, “assists” and “supports” were present. However, Products A and B provided 
conflicting information on the immediate container label and the outer container label, as 
reflected in Table 4-2. Since the immediate container label did not contain the term 
“supportive” and merely stated “recommended”, this could be interpreted as a medicinal 
claim. The immediate container label was deemed non-compliant.  
 
 Labelling Requirements in Terms of Act 101 of 1965 4.4
 
4.4.1 Regulation 8: Information on Immediate and Outer Container Labels 
 
Table 4-7 Information on immediate and outer container labels as required by regulation 8 of Act 101 of 1965. 
Immediate label n = 13  
Outer label n = 11 
 
Requirements  Immediate container label 
 
Outer container label 
 
Number of 
products 
compliant 
Number of 
products 
partially 
compliant 
Number 
of 
products 
non-
compliant 
 
Number 
of 
products 
compliant 
Number of 
products 
partially 
compliant 
Number of 
products  
non- 
compliant 
Scheduling status 
(where applicable) 
1 0 12 1 0 10 
Proprietary name of 
the medicine 
 
13 0 0 11 0 0 
Registration/reference 
number 
 
1 0 12 1 0 10 
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Requirements  Immediate container label 
 
Outer container label 
 
Number of 
products 
compliant 
Number of 
products 
partially 
compliant 
Number 
of 
products 
non-
compliant 
 
Number 
of 
products 
compliant 
Number of 
products 
partially 
compliant 
Number of 
products  
non- 
compliant 
Dosage form 
 
12 0 1 11 0 0 
Approved name of 
each active ingredient 
of the medicine 
 
13 0 0 11 0 0 
Quantity thereof 
contained in a dosage 
unit, or per suitable 
mass or volume or 
unit 
 
11 0 2 10 0 1 
Content of the 
medicine package 
expressed in the 
appropriate 
unit or volume of the 
medicine 
 
11 0 2 11 0 0 
Lot number 
 
13 0 0 11 0 0 
Expiry date 
 
13 0 0 11 0 0 
Name of the holder of 
certificate of 
registration (or name 
of applicant) 
 
12 0 1 11 0 0 
Storage temperature 
and other precautions 
required for the 
preservation of the 
medicine 
 
12 0 1 11 0 0 
The warning: “Keep 
out of reach of 
children” 
 
12 0 1 11 0 0 
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Figure 4-2 Graph illustrating compliance with Information on immediate and outer container labels as 
required by regulation 8 of Act 101 of 1965. 
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All the products contained a label affixed to the immediate container, featuring text in 
English. Eleven of the products featured an outer container label. Only one product, 
Product G, contained a scheduling status (S 0). While medicines in this category of CMs 
are not scheduled, there should still be information in the package insert stating that the 
product is unscheduled, or S 0.  
Only two of the products contained information pertaining to the preservative content. 
Product I stated that it contained no preservatives, and only the outer container label of 
Product E stated that alcohol was the preservative. Product E was the only product 
stating sugar content, and while Product G stated that it contained sugar, it did not 
provide the quantity thereof. Products A and E provided alcohol content information. 
None of the products contained a tartrazine warning. Since the product formulations 
were not evaluated in this study, it cannot be determined if the products required this 
warning.  
The products were assessed to determine whether the indications were provided. The 
accuracy of the indications has been discussed in 4.2.3 (Therapeutic Indications). 
Products C and H did not contain any indications on their immediate labels, but both 
contained the indications on the outer label. Similarly, dosage was only assessed for 
presence, not accuracy. The immediate labels of products H and I were non-compliant, 
as the only dosage instruction was to refer to the package insert. However, the outer 
labels of these two products provided the dosage instructions.  
One product contained a “Reg. No.” on its immediate and outer container label, while 
this was deemed compliant in that a number was provided, the terminology “Reg. No.” 
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which was used is not correct. No CMs have yet been evaluated by the MCC, and 
therefore referring to the number provided as a registration number implies that the 
product has undergone evaluation and is approved. The more appropriate term is 
“complementary registry number”, as seen in the package inserts of some of the 
products. It is most likely that the number referenced is not a registration number, but a 
registry number, provided by the MCC during the call up in 2002.  This is confirmed by 
the product’s package insert, whereby the “registration number” contained a statement 
that the registration number was “to be allocated”.   
 
4.4.2 Regulation 9: Information on Package Inserts 
 
Two of the products did not contain package inserts, and therefore were deemed non-
compliant with all the package insert requirements. Subsequent analysis refers only to 
the products that contained package inserts. For a summary of the information present 
in the package inserts, refer to Table 4-8.  
One product provided a “product information leaflet” containing similar information to 
that required by the package insert, but the information was not provided in the format 
of the package insert requirements. All the package inserts were in English, and nine 
were in Afrikaans as well.  
Compliance with the scheduling status requirement was fulfilled if information was listed 
either as S 0, “not scheduled”, or “not applicable”. One product was deemed partially 
compliant as it stated “nutritional supplement” under the scheduling status. 
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Compliance was granted for the reference number requirement if relevant information 
was provided, such as the number, or the phrases “to be allocated” or “pending”. Two 
products contained postal address information instead of the physical address, and 
were deemed non-compliant.  
Table 4-8 Information appearing on the package insert of products (n=11) as compared to the requirements 
as stipulated in Act 101 of 1965. 
Required information Number of 
products 
compliant 
Number of 
products partially 
compliant 
Number of 
products non-
compliant 
Scheduling status (where 
applicable) 
7 
 
1 
 
3 
Proprietary name and 
dosage form 
 
11 0 0 
The approved name of 
each active ingredient  
 
11 0 0 
Quantity thereof 
contained in a dosage unit 
or per suitable mass or 
volume or unit of the 
medicine 
 
10 1 
 
0 
Identification 
 
11 0 0 
Presentation 11 0 0 
Storage instructions, 
including storage 
temperatures 
7 4 
 
0 
Reference number (where 
applicable) followed by 
the expression:  
"Act 101/1965" 
9  0 2 
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Required information Number of 
products 
compliant 
Number of 
products partially 
compliant 
Number of 
products non-
compliant 
Name and business 
address of the holder of 
the certificate of 
registration/applicant 
9 0 2  
Date of publication of the 
package insert (where 
applicable) 
10 0 1 
 
 
0
2
4
6
8
10
12
Number of products compliant Number of products partially compliant
Number of products non-compliant
 
 
 
 
58 
 
Figure 4-3 Graph illustrating compliance of information appearing on the package insert of products (n=11) 
as compared to the requirements as stipulated in Act 101 of 1965. 
 
 
Only product E provided information about preservative content. Compliance or non-
compliance regarding preservative information could not be determined in the other 
products, as it was not known if their formulation included preservatives. It is likely that 
they would contain preservatives, however, in which case they would be non-compliant. 
Two of the liquid formulations provided information about their alcohol content, and 
were therefore compliant. Products C, G and M contained information pertaining to 
sugar.  
Nine of the products were deemed compliant for containing a reference number, in that 
they either contained the statement “to be allocated” or the provided number was 
preceded by: “complementary registry number”. This demonstrated that the numbers 
were not medicine registration numbers, and that the products had not been evaluated. 
 
4.4.2.1 Pharmacological Classification and Pharmacological Action 
 
The MCC has classified immune boosters under: 32.16 (Other) Immune Boosters 
(MCC, 2013b). Various classifications appeared in the package inserts. The results for 
this section are depicted in Figure 4-1 (presented overleaf). 
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Figure 4-4 Pharmacological classification as per the package insert of the sampled products (n=11).  
Category D.22.2 Vitamins-Other (Naturopathy) is not correct. Even though the product 
contained vitamins, its Western Herbal discipline is not recognised. Category A.22.2 is 
likely to be outdated as CMs now fall under Category D. Similarly, Category A 32.2-
Other would be outdated, even in the case where the manufacturer has stated that it is 
a complementary medicine. Four of the products were classified under category A. 34, 
but this category was not found in the Regulations of Act 101 of 1965. These results 
demonstrate that there is uncertainty as to which classification should be used. Nine of 
the products contained information under the pharmacological action heading. 
  
1 1 1 1 
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4.4.2.2 Sections Corresponding to the European Medicines Agency Monographs 
 
The sections presented in Table 4-9 were assessed to determine if information was 
provided under the required headings of Regulation 9 of Act 101 of 1965. Products were 
deemed compliant if the information was in accordance with the information presented 
in the monographs. Products were deemed partially compliant if information was 
provided in the package insert, but was not consistent with the monographs. Products 
were deemed non-compliant if no information was provided. 
Table 4-9 Compliance with Regulation 9 sections corresponding to European Medicines 
Agency (EMA) monograph (n=11). 
Heading Product 
 
 A B C D E F G I J L M 
Indications 
 
+ + + + + + + + + + + 
Contra-
indications 
 
= = + + = = + = + = = 
Warnings 
 
= = = = = = + = - = = 
Interactions = = = = + + = - - - = 
Pregnancy  
 
+ + + + + + + + - + = 
Dosage and 
directions 
for use 
 
+ + + + + + + + + + + 
Side effects 
and special 
precautions 
 
+ + = = = = = = = + = 
Known 
symptoms 
of 
overdosage 
and 
particulars 
+ + + + + + + + + + + 
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Heading Product 
 
 A B C D E F G I J L M 
of its 
treatments 
 
 
Key:  
+ Complies in that information was provided 
= Complies with EMA monograph 
- Non-compliant 
 
4.4.3 Regulation 10: Information on Patient Information Leaflets 
 
Only product G contained a patient information leaflet. As there was only one patient 
information leaflet available for the study, no further analysis was conducted into 
compliance in this regard. 
 
 Limitations of the Study 4.5
 
The majority of the products did not conform to the EMA monographs. A limitation of 
this study is that only EMA monographs were used to assess compliance, and perhaps 
the use of other monographs recognised by the MCC would provide additional 
information surrounding compliance. However, the EMA remains a reputable and MCC-
recognised reference source. 
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Another limitation is that the labelling of the products in this study may have been 
superseded with conformant labelling by the time of this writing. CM companies may 
have revised and updated product labelling in order to comply with the MCC’s 
guidelines, and these new batches of products could now be available on the market.  
  
4.6 Overall Compliance 
 
An overall percentage compliance for each product was allocated to each of the three 
sections of the data collection tool. This was determined by assigning each variable a 
level of compliance as follows: 0 for non-compliance; 0,5 for partial compliance or where 
information only complied in that it was provided; and 1 for total compliance. In order to 
determine the percentage of compliance, the total value was added up and divided by 
the number of headings. Appendix 3 details the variables included and excluded in the 
assessment. The overall compliance of each product with each section of the data 
assessment is demonstrated below, in Figures 4-2 to 4-4. 
  
Figure 4-5 Percentage compliance of each product with the European Medicines Agency monograph.   
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Figure 4-6 Percentage compliance of each product with the Medicine Control Council’s minimum 
requirements. 
 
 
Figure 4-7 Percentage compliance of each product with Regulations 8 and 9 of Act 101 of 1965. 
 
 
 
0
20
40
60
80
100
120
0
10
20
30
40
50
60
70
80
90  
 
 
 
64 
 
5 Conclusions 
 
 Quality  5.1
 
The study of the monographs affirmed the importance of composition, as a specific part 
of the herbal plant is required to achieve a product’s intended therapeutic indications. 
Furthermore, the results of the literature search demonstrated that plant composition 
may have a direct impact on efficacy. However, due to a lack of information about the 
composition of the products in this study, it was difficult to determine quality compliance 
with the corresponding monograph. Therefore, CM companies applying for registration 
will need to submit detailed and accurate information about product composition. In turn, 
regulators will be responsible for verifying this information before approving product 
registration.  
Some of the products presented conflicting data between the package inserts and 
labels. This demonstrated a poor quality of data presentation, and is not acceptable as 
inconsistent dosage or composition information will cause patient confusion. It also 
demonstrates that the applicant has poor control over its internal regulatory processes, 
which may be due to a lack of Good Manufacturing Practice (GMP). Applicants should 
ensure that product labelling does not provide conflicting information, and stricter 
regulatory labelling approval processes will need to be created and followed. 
 Efficacy 5.2
 
All the products were non-compliant with regard to indications because they contained 
therapeutic indications that were not stated in the monographs. While the literature 
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search provided some support for the flu indication, these studies would not satisfy the 
MCC’s requirements. Applicants are required to conduct an extensive and well-
balanced literature search when applying for evidence of efficacy, if efficacy cannot be 
obtained from a recognised source, such as the Martindale (MCC, 2013a). 
Products were non-compliant with regard to posology. Underdosing could lead to a lack 
of efficacy, which could result in increased morbidity. Overdosing could result in toxicity 
and compromise patient safety.   
 Safety 5.3
 
Correct information with regard to contra-indications is essential for safety. On the one 
hand, it was promising to see that eleven of the thirteen products in the study were 
deemed compliant in reflecting the contra-indications as per the monographs. On the 
other hand, some products did not comply fully with the special warnings, such as the 
labels that did not contain the hepatotoxicity risk related to Pelargonium. Use of these 
products in susceptible patients could have detrimental consequences. Furthermore, 
product labelling without warnings could lead to a false perception of safety.  
It was concerning to find that only two of the thirteen products complied fully with the 
monographs’ information pertaining to pregnancy and lactation. Since all but one of the 
monographs stated that there was insufficient safety data to prescribe use during 
pregnancy and lactation, the product labelling should state that safety in this regard has 
not been established.  
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 MCC Labelling Compliance 5.4
 
 
The MCC has mandated that CMs contain the statement that the CM has not been 
MCC-evaluated (MCC, 2013). Only 46% of the products in this study contained this 
statement. This is a significant non-conformance, since this requirement should have 
been implemented by May 2014 (MCC, 2013b). 
The majority of the products complied only partially with the requirements of Regulation 
8, and 77% of the products did not contain text in a language other than English. This 
poses a risk that patients who do not understand English could misuse the product. 
While these products were not required to comply with Regulation 8 at the time of this 
study, applicants will have to correct their labelling to align with the future requirements.   
All the products contained batch numbers (a necessary GMP requirement for product 
traceability), as well as expiry dates (which may affect product safety and efficacy).   
Pharmacological classifications were provided for the majority of the products, but there 
were slight variations in the classification chosen. It must be considered that some of 
the products contained vitamins, minerals, and even other herbal ingredients not 
recognised by the EMA monographs. In such cases it would be difficult for the applicant 
to determine the appropriate pharmacological classification. It is recommended that the 
MCC provide CM companies with further guidance in the selection of correct 
pharmacological classifications. This could be done in a workshop or at a conference.  
Based on the results of this study, CMs are not yet fully compliant with either the 
prescribed EMA monographs or the MCC’s requirements. None of the products 
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investigated were compliant with the MCC’s mandatory minimum labelling 
requirements. Applicants should urgently revise their product labelling to comply with 
the minimum labelling requirements.  
The minimum labelling requirements are simpler to fulfil than those necessary for 
product approval. Therefore, if applicants are unable to meet these requirements, there 
is a likelihood that they will struggle to provide the complex data required for product 
registration. 
Further research should be conducted regarding the challenges faced by the CM 
industry in obtaining the data they require for MCC evaluation and approval. It would 
also be beneficial to investigate what challenges the MCC faces in evaluating CM 
submissions. The CM industry and the MCC are encouraged to work together in this 
multifaceted challenge of CM regulation, to assure that marketed Complementary 
Medicines are of a suitable quality, are safe, and are effective.  
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7 Appendices 
 
7.1 Appendix 1: Research Proposal  
 
Title 
An evaluation of Western Herbal Complementary Medicine labelling in South Africa, to 
determine whether the product labelling information complies with established herbal 
monographs and whether it meets local regulatory requirements.  
 
Introduction 
In South Africa, Complementary Medicines (CMs) have come under increased scrutiny 
in the past few years. CMs are widely used by the South African public (MCC, 2013), 
and in 2013 the South African Medicines Control Council (MCC) published guidelines to 
improve the regulation of these products (MCC, 2013). An important component of 
these guidelines pertains to labelling requirements. Product labelling includes the 
container labels, package inserts and patient information leaflets. Appropriate labelling 
is necessary to provide consumers with information on how to use the product correctly 
and safely.  
Western Herbal Medicines is categorised as a CM discipline (MCC, 2013). This 
research project aims to study the labelling of selected Western Herbal Medicines.  
Specifically, products falling under the category of “immune boosters” will be studied. 
The MCC has classified immune boosters under 32.16 (Other) and requires that these 
comply with the CM guidelines by May 2016 (MCC, 2013).  
The labelling of the products selected will be assessed to determine whether pertinent 
information such as the indications, recommended dosages, contra-indications and side 
effects is in accordance with recognised herbal monographs. The labelling will also be 
assessed for compliance with the MCC’s regulatory requirements. The data obtained 
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from this research will provide further information into the current status of Western 
Herbal Medicine labelling compliance.  
 
Methodology 
Literature Search 
A literature search will review the MCC’s current CM guidelines, and the Medicines and 
Related Substances Act (Act No. 101 of 1965), to establish the requirements for the 
labelling of CMs. The European Medicines Agency (EMA) database of Community 
Herbal Monographs will be searched to obtain the relevant herbal monographs for the 
active ingredients contained in the products identified in this study.  
Demographic Area 
The demographic area chosen for this study is the Northern Suburbs of Johannesburg. 
These suburbs are close to the Johannesburg and Sandton CBDs as well as the 
middle-class suburbs. There is a wide selection of large-chain pharmacies as well as 
smaller, privately owned pharmacies and health shops in these areas. These contain a 
wide selection of the various marketed brands of Western Herbal Medicines, and 
therefore the inclusion of these stores will provide a broad sample of the immune-
boosting Western Herbal Medicines required for this study.  
Product Selection 
The inclusion criteria of the products selected will include labelling which indicates that 
the product may be used for immune-enhancing effects, and contains one or more 
active ingredients listed in the EMA community herbal monographs, as these are 
recognised by the MCC (MCC, 2013).  
Labelling Assessment 
A labelling assessment form will be created based on the MCC’s requirements. This 
form will reference the information prescribed in the corresponding EMA herbal 
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monograph in order to compare it with the product’s information. The assessment form 
will also include the information that the MCC requires all CM labelling to have with 
immediate effect, as well as the information that will be required by the May 2016 
deadline.  
Each product will be recorded on the data collection checklist using the product’s trade 
name, and its corresponding labelling information will also be captured. The collected 
data will be then be analysed in order to determine the percentages of products in the 
sample that complied or did not comply with the various labelling requirements. These 
results will provide a conclusion as to the current status of labelling compliance of 
Western Herbal CMs.   
 
Ethical Considerations 
The labelling assessment form will be submitted to the Ethics Committee for approval.  
This research does not involve patients nor healthcare professionals, therefore ethical 
approval for research subjects is not required. However, there are still ethical issues to 
consider regarding the promotion and marketing of these products. The names of the 
pharmacies and health shops from which products are bought will be kept confidential. 
However, the proprietary names of the products obtained will be used, as this 
information is freely available within the public domain. Furthermore, the results 
obtained are for the sole purpose of obtaining the information required for this research 
topic, and have no association with the promotion nor disparagement of the products. 
The manufacturing companies producing the products have no involvement with this 
research project and this research has no financial interests.  
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7.2 Appendix 2: Data Collection Tool 
 
 
 
Western Herbal Complementary Medicines Labelling Assessment Form 
Trade Name:  
 
Active Ingredient/s: 
 
1. EMA Herbal Monograph: 
Date of compilation/last revision: 
 
Heading EMA Herbal 
Monograph 
Product Label Complies Non-
Compliant 
Qualitative and 
quantitative composition 
 
    
Pharmaceutical Form 
 
    
Therapeutic indications 
 
    
Posology 
 
    
Duration of use     
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Heading EMA Herbal 
Monograph 
Product Label Complies Non-
Compliant 
 
Method of administration 
 
    
Contraindications 
 
    
Interactions with other 
medicinal products and 
other forms of interaction 
 
    
Pregnancy and lactation 
 
    
Effects on ability to drive 
and use machines 
 
    
Undesirable effects 
 
    
Overdose     
 
Comments: (Does the product comply with the information prescribed by the EMA monograph?) 
  
 
 
2. MCC prescribed minimum information  
(Required to have been implemented by 15 May 2014) 
Criteria  Information on Label 
(Provide Description) 
Complies Non-Compliant 
 
Written in English and at least one 
other official language  
 
   
Category of medicine  
 
 
   
Pharmacological classification of the 
medicine  
 
   
Discipline of medicine  
 
   
The words “This medicine has not    
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Criteria  Information on Label 
(Provide Description) 
Complies Non-Compliant 
been evaluated by the Medicines 
Control Council. This medicine is not 
intended to diagnose, treat, cure or 
prevent any disease” 
 
All claims relating to symptoms must 
be accompanied by the advice “If 
symptoms persist consult your 
healthcare practitioner” 
 
   
No medicinal claims: 
 
Immediate label 
   
Carton    
Package Insert    
Patient Information Leaflet    
 
Comments: (Does the product comply with the minimum mandatory labelling information?) 
 
3. Labelling Requirements in terms of Medicines and Related Substances 
Act, 1965  
Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
Label (Regulation 8 of the Act)    
Present/Absent 
 
   
Affixed to immediate container 
 
   
Clearly legible indelible letters in 
English  
 
   
Clearly legible indelible letters in at 
least one other official language 
 
   
Scheduling status (where applicable) 
 
   
Proprietary name of the medicine 
 
   
Registration/Reference Number 
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Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
Dosage form  
 
   
Approved name of each active 
ingredient of the medicine  
 
   
Quantity thereof contained in a 
dosage unit, or per suitable mass or 
volume or unit 
 
   
Name and percentage of any 
bacteriostatic or bactericidal agent 
which has been added to the medicine 
as a preservative 
 
   
Approved name of any anti-oxidant 
contained in the medicine 
 
   
Quantity of sugar contained in the 
medicine  
   
Quantity of ethyl alcohol contained in 
the medicine, expressed 
as a percentage of the total volume of 
the medicine if such quantity exceeds 
two per cent by volume 
 
   
Content of the medicine package 
expressed in the appropriate 
unit or volume of the medicine 
 
   
Approved indications for use of the 
medicine 
 
   
Recommended dosage of the 
medicine 
 
   
Where applicable, the instruction 
'Shake the bottle before use' 
 
   
Lot number 
 
   
Expiry date 
 
   
Name of the holder of certificate of 
registration (or name of applicant) 
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Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
 
Storage temperature and other 
precautions required for the 
preservation of the medicine 
 
   
The warning: 'Keep out of reach of 
children' 
 
   
If the medicine contains TARTRAZINE, 
the warning: 
'Contains TARTRAZINE’ 
 
   
Carton (where applicable) 
 
 
   
Clearly legible indelible letters in 
English  
 
   
Clearly legible indelible letters in at 
least one other official language 
 
   
Scheduling status (where applicable) 
 
   
Proprietary name of the medicine 
 
   
Registration/Reference Number 
 
 
   
Dosage form  
 
   
Approved name of each active 
ingredient of the medicine  
 
   
Quantity thereof contained in a 
dosage unit, or per suitable mass or 
volume or unit 
 
   
Name and percentage of any 
bacteriostatic or bactericidal agent 
which has been added to the medicine 
as a preservative 
 
   
Approved name of any anti-oxidant 
contained in the medicine 
 
   
 
 
 
 
84 
 
Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
Quantity of sugar contained in the 
medicine  
   
Quantity of ethyl alcohol contained in 
the medicine, expressed 
as a percentage of the total volume of 
the medicine if such quantity exceeds 
two per cent by volume 
 
   
Content of the medicine package 
expressed in the appropriate 
unit or volume of the medicine 
 
   
Approved indications for use of the 
medicine 
 
   
Recommended dosage of the 
medicine 
 
   
Where applicable, the instruction 
'Shake the bottle before use' 
 
   
Lot number 
 
   
Expiry date 
 
   
Name of the holder of certificate of 
registration (or name of applicant) 
 
   
Storage temperature and other 
precautions required for the 
preservation of the medicine 
 
   
The warning: 'Keep out of reach of 
children' 
 
   
If the medicine contains TARTRAZINE, 
the warning: 
'Contains TARTRAZINE’ 
 
   
Package Insert (Regulation 9 of the 
Act) 
 
   
Present/Absent 
 
   
Clearly legible text in English      
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Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
 
Clearly legible text in at least one 
other official language 
 
   
Scheduling status (where applicable) 
 
   
Proprietary name and dosage form 
 
   
The approved name of each active 
ingredient  
 
Quantity thereof contained in a 
dosage unit or per suitable mass or 
volume or unit of the medicine 
 
   
The approved name and quantity of 
any bactericidal or bacteriostatic 
agent included in the medicine as a 
preservative , expressed as a 
percentage 
 
   
The quantity of ethyl alcohol included 
in a preparation for oral or parenteral 
administration, if such quantity 
exceeds two per cent by volume 
 
   
The words " contains TARTRAZINE" 
should the medicine contain such 
ingredient 
 
   
"contains sugar" or "sugar free" 
whichever is applicable 
 
   
Pharmacological classification 
 
 
   
Pharmacological action 
 
   
Indications 
 
   
Contra-indications 
 
   
Warnings 
  
   
Interactions    
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Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
 
Pregnancy and lactation 
 
   
Dosage and directions for use 
 
   
Side effects and special precautions 
 
   
Known symptoms of over dosage and 
particulars of its treatments 
 
   
Identification 
 
   
Presentation 
 
   
Storage instructions, including  
storage temperatures 
 
   
Reference number (where applicable) 
followed by the expression " Act 
101/1965" 
 
   
Name and business address of the 
holder of the certificate of 
registration/applicant 
 
   
Date of publication of the package 
insert (where applicable) 
 
   
Patient Information Leaflet 
(Regulation 10 of the Act) 
 
 
   
Present/Absent 
 
   
Scheduling status 
 
   
Proprietary name and dosage form 
 
   
The composition of the medicine 
 
   
The approved indications and use 
 
   
Instructions on how to take the 
medicine, including: 
   
Contra-indications    
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Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
 
Precautions 
 
   
Warnings (e.g. concerning sedative 
properties of the 
medicine or risks involved with sudden 
withdrawal of 
the medicine) 
 
   
Interactions 
 
   
The following general statements: 
"If you are taking medicines on a 
regular basis, using the medicine at 
the same time with another medicine 
may cause undesirable interactions.  
 
Please consult your  
doctor, pharmacist or other health 
care professional for advice." 
 
"If you are pregnant or breast feeding 
your 
baby while taking this medicine please 
consult your doctor, pharmacist or 
other 
health care professional for advice. 
 
   
Instructions on how to take the 
medicine, including the following 
statements: 
"Do not share medicines prescribed 
for you with any other 
person. " 
 
"In the event of over dosage, consult 
your doctor or pharmacist. If neither is 
available, contact the nearest 
hospital or poison control centre" 
 
   
Side effects, including the following 
general statement: 
 
"Not all side-effects reported for this 
medicine are included in 
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Label Criteria Information on Label 
(Provide Description) 
Complies Non-Compliant 
this leaflet. Should your general health 
worsen while taking 
this medicine, please consult your 
doctor, pharmacist or 
other health care professional for 
advice" 
 
Storage and disposal information, 
including the following general 
statement: 
 
"store all medicines out of reach of 
children." 
 
   
Presentation, which includes the 
number, volume or mass per 
package unit and a description of the 
packaging material, e.g. bottle, 
blister pack, etc 
 
   
Identification of the medicine, i.e. the 
description of its physical 
appearance as tablet, capsule, etc 
 
   
Registration number of the medicine 
 
   
Name, business address and 
telephone number of the holder of 
the certificate of 
registration/applicant 
 
   
Date of publication of the patient 
information leaflet 
 
   
 
Comments: (Does the product comply with the Labelling requirements of the Medicines Act? Product 
will be required to demonstrate compliance by latest May 2016) 
 
 
 
 
 
 
89 
 
 Appendix 3: Criteria used to assess percentage of compliance 7.3
 
Compliance with EMA monographs 
Variable Included Variable Excluded Reason for exclusion 
Pharmaceutical Form Qualitative and quantitative 
composition 
 
Not all products could be 
determined as there is not 
sufficient quality related data 
available 
Therapeutic indications 
 
Pharmaceutical Form 
 
Not all products could be 
determined as there is not 
sufficient quality related data 
available 
Posology 
 
  
Duration of use 
 
  
Method of administration 
 
  
Contraindications 
 
  
Special warnings and 
precautions for use 
 
  
Interactions with other 
medicinal products and 
other forms of interaction 
 
  
Pregnancy and lactation 
 
  
Effects on ability to drive 
and use machines 
 
  
Undesirable effects 
 
  
Overdose 
 
  
 
Compliance with MCC minimum prescribed requirements 
Variable Included Variable Excluded Reason for exclusion 
The words “This medicine 
has not been evaluated by 
the Medicines Control 
Council. This medicine is 
not intended to diagnose, 
treat, cure or prevent any 
Written in English and at 
least one other official 
language  
 
Evaluated in the section of 
compliance with Regulation 8. 
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disease” 
 
All claims relating to 
symptoms must be 
accompanied by the advice 
“If symptoms persist consult 
your healthcare practitioner” 
 
No medicinal claims Only the immediate labels of two 
products did not comply with this.  
Category of medicine   
 
Pharmacological 
classification of the 
medicine  
 
  
Discipline of Medicine    
 
Compliance with Regulation 8 of Act 101 of 1965 (Label) 
 
Variable Included 
 
Variable Excluded Reason for exclusion 
Immediate container label 
only 
Outer container label Not all products contained one 
Present Approved name of any anti-
oxidant contained in the 
medicine 
 
Could not be determined if the 
products contained these 
ingredients, therefore this was  
not applicable to all products 
Affixed to immediate 
container 
Quantity of sugar contained 
in the medicine 
Clearly legible indelible 
letters in English 
 
Quantity of ethyl alcohol 
contained in the medicine, 
expressed 
as a percentage of the total 
volume of the medicine if 
such quantity exceeds two 
per cent by volume 
 
Clearly legible indelible 
letters in at least one other 
official language 
 
If the medicine contains 
TARTRAZINE, the warning: 
'Contains TARTRAZINE’ 
 
Scheduling status (where 
applicable) 
 
Where applicable, the 
instruction 'Shake the bottle 
before use' 
 
Not applicable to oral solid 
dosage forms 
Proprietary name of the 
medicine 
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Variable Included 
 
Variable Excluded Reason for exclusion 
Registration/Reference 
Number 
 
  
Dosage form 
 
  
Approved name of each 
active ingredient of the 
medicine 
 
  
Quantity thereof contained 
in a dosage unit, or per 
suitable mass or volume or 
unit 
 
  
Name and percentage of 
any bacteriostatic or 
bactericidal agent which has 
been added to the medicine 
as a preservative 
 
  
Content of the medicine 
package expressed in the 
appropriate unit or volume 
of the medicine 
 
  
Approved indications for use 
of the medicine 
 
  
Recommended dosage of 
the medicine 
 
  
Lot number 
 
  
Expiry date 
 
  
Name of the holder of 
certificate of registration (or 
name of applicant) 
 
  
Storage temperature and 
other precautions required 
for the preservation of the 
medicine 
 
  
The warning: 'Keep out of 
reach of children' 
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Compliance with Regulation 9 of Act 101 of 1965 (Package Insert) 
Variable Included Variable Excluded Reason for exclusion 
Clearly legible text in 
English  
 
The quantity of ethyl alcohol 
included in a preparation for 
oral or parenteral 
administration, if such 
quantity exceeds two per 
cent by volume 
 
Not applicable to all of the 
products 
Clearly legible text in at 
least one other official 
language 
 
The words " contains 
TARTRAZINE" should the 
medicine contain such 
ingredient 
 
Scheduling status (where 
applicable) 
 
Pharmacological 
classification 
 
Discussed separately 
Proprietary name and 
dosage form 
 
  
The approved name of each 
active ingredient  
 
  
Quantity thereof contained 
in a dosage unit or per 
suitable mass or volume or 
unit of the medicine 
 
  
"contains sugar" or "sugar 
free" whichever is applicable 
 
  
Pharmacological action 
 
  
Indications 
 
  
Contra-indications 
 
  
Warnings 
 
  
Interactions 
 
  
Pregnancy and lactation 
 
  
Dosage and directions for 
use 
 
  
Side effects and special   
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Variable Included Variable Excluded Reason for exclusion 
precautions 
 
Known symptoms of over 
dosage and particulars of its 
treatments 
 
  
Identification 
 
  
Presentation 
 
  
Storage instructions, 
including  
storage temperatures 
 
  
Reference number (where 
applicable) 
followed by the expression " 
Act 
101/1965" 
 
  
Name and business address 
of the holder of the 
certificate of 
registration/applicant 
 
  
Date of publication of the 
package insert (where 
applicable) 
 
  
 
 
 
 
 
 
